General Science and Philosophy

2205 Submissions

[4] viXra:2205.0154 [pdf] replaced on 2023-10-30 21:10:08

Unprovability of First Maxwell's Equation in Light of EPR's Completeness Condition

Authors: Abhishek Majhi
Comments: 17 Pages. Pramana — J. Phys. (2023) 97:163, https://doi.org/10.1007/s12043-023-02594-1

Maxwell's verbal statement of Coulomb's experimental verification of his hypothesis, concerning force between two electrified bodies, is suggestive of a modification of the respective computable expression on logical grounds. This modification is in tandem with the completeness condition for a physical theory, that was stated by Einstein, Podolsky and Rosen in their seminal work. Working with such a modification, I show that the first Maxwell's equation, symbolically identifiable as ``$\vec{\nabla}\cdot\vec{E}=\rho/\epsilon_0$'' from the standard literature, is {\it unprovable}. This renders Poynting's theorem to be {\it unprovable} as well. Therefore, the explanation of `light' as `propagation of electromagnetic energy' comes into question on theoretical grounds.
Category: General Science and Philosophy

[3] viXra:2205.0081 [pdf] submitted on 2022-05-15 14:56:34

Life Looks Like an Axiom to us

Authors: Vladimir Aksayskiy
Comments: 2 Pages.

The dynamics of human evolution and the visible universe are similar.
Category: General Science and Philosophy

[2] viXra:2205.0057 [pdf] submitted on 2022-05-09 07:32:12

On the Renormalization of Scientific Citations

Authors: István Daruka
Comments: 6 Pages.

Through a comparative example, this paper calls for the necessity of the renormalization of scientific citations due to the exponentially inflating citation horizon.
Category: General Science and Philosophy

[1] viXra:2205.0034 [pdf] submitted on 2022-05-06 20:05:14

Halting Severe Chemotherapy Toxicity and Improving Patient Outcomes in Cancer Treatment

Authors: Dean Tatlow, Corinne Tatlow, Scarlet Tatlow, Savanah Tatlow
Comments: Pages.

In cancer treatment, there is a narrow therapeutic window with chemotherapy agents. The most common reason for chemotherapy dose reduction is neutropenia resulting in impaired survival. Chemotherapy dosage is calculated based on body surface area, with no adjustment recommendation for a patient's albumin level even though chemotherapy medications are highly protein-bound. The insight gained by mathematical modeling suggests an altered free/bound drug ratio in patients with low albumin results in severe side effects. Furthermore, mathematical modeling also reveals impaired survival in dose-reduced chemotherapy patients may be from decreased bound drug levels while free drug levels remain unchanged. Restoring the free/bound drug ratio by correcting a patient's albumin deficit will reduce chemotherapy side effects and improve patient outcomes. Finally, enhanced chemotherapy treatment is possible by capping the free drug level and maximizing the bound drug level. The mathematical model predicts the following chemotherapy medications will have altered free/bound drug ratio in patients with low albumin: cisplatin, oxaliplatin, doxorubicin, epirubicin, idarubicin, paclitaxel, eribulin, etoposide, vinorelbine, bendamustine, chlorambucil, and pemetrexed.
Category: General Science and Philosophy